CDTX
USDCidara Therapeutics Inc. Common Stock
Preço em tempo real
Gráfico de preços
Métricas-chave
Métricas de mercado
Abertura
$101.450
Máximo
$105.280
Mínimo
$100.160
Volume
0.70M
Fundamentos da empresa
Capitalização de mercado
2.5B
Setor
Biotecnologia
País
United States
Estatísticas de negociação
Volume médio
0.84M
Bolsa de valores
NCM
Moeda
USD
Faixa de 52 semanas
Notícias relacionadas
Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025
SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today
Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10ᵗʰ ESWI Influenza Conference 2025
SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today
HC Wainwright & Co. Reiterates Buy on Cidara Therapeutics, Maintains $150 Price Target
HC Wainwright & Co. analyst Sara Nik reiterates Cidara Therapeutics with a Buy and maintains $150 price target.
Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today
Cidara Therapeutics Analyst Says Lead Influenza Candidate Is 'Strategically Attractive'
JP Morgan initiated coverage on Cidara Therapeutics with Overweight rating & tgt of $200, citing lead flu asset CD388's game-changing potential.
Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025
SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today
JP Morgan Initiates Coverage On Cidara Therapeutics with Overweight Rating, Announces Price Target of $200
JP Morgan analyst Anupam Rama initiates coverage on Cidara Therapeutics with a Overweight rating and announces Price Target of $200.
Ações relacionadas
Mantenha-se atualizado
Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.